TY - JOUR
T1 - Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease
T2 - A Randomized Controlled Trial
AU - Panahi, Yunes
AU - Kianpour, Parisa
AU - Mohtashami, Reza
AU - Jafari, Ramezan
AU - Simental-Mendía, Luis E.
AU - Sahebkar, Amirhossein
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Objective Non-alcoholic fatty liver disease (NAFLD) is a common liver disease characterized by excess lipid deposition in the hepatic tissue and subsequent oxidative and inflammatory damage. Curcumin is a dietary polyphenol with lipid-modifying, antioxidant and anti-inflammatory properties. This study aimed to evaluate the efficacy and safety of supplementation with phytosomal curcumin in subjects with NAFLD. Methods Patients diagnosed with NAFLD (grades 1–3 according to liver ultrasonography) were randomly assigned to the curcumin (phytosomal form; 1 000 mg/day in 2 divided doses) (n=50) or placebo group (n=52) for a period of 8 weeks. All patients received dietary and lifestyle advises before the start of trial. Anthropometric measurements, hepatic enzymes, and liver ultrasonography were assessed at baseline and after 8 weeks of follow-up. Results 87 subjects (n=44 and 43 in the curcumin and control group, respectively) completed the trial. Supplementation with curcumin was associated with a reduction in body mass index (–0.99±1.25 vs. – 0.15±1.31 in the curcumin and placebo groups, respectively; p=0.003) and waist circumference (–1.74±2.58 vs. –0.23±3.49 in the curcumin and placebo groups, respectively; p=0.024). Ultrasonographic findings were improved in 75.0% of subjects in the curcumin group, while the rate of improvement in the control group was 4.7% (p<0.001). Serum levels of aspartate aminotransferase and alanine aminotransferase were reduced by the end of trial in the curcumin group (p<0.001) but elevated in the control group (p<0.001). Curcumin was safe and well tolerated during the course of trial. Conclusion Short-term supplementation with curcumin improves liver fat and transaminase levels in patients with NAFLD.
AB - Objective Non-alcoholic fatty liver disease (NAFLD) is a common liver disease characterized by excess lipid deposition in the hepatic tissue and subsequent oxidative and inflammatory damage. Curcumin is a dietary polyphenol with lipid-modifying, antioxidant and anti-inflammatory properties. This study aimed to evaluate the efficacy and safety of supplementation with phytosomal curcumin in subjects with NAFLD. Methods Patients diagnosed with NAFLD (grades 1–3 according to liver ultrasonography) were randomly assigned to the curcumin (phytosomal form; 1 000 mg/day in 2 divided doses) (n=50) or placebo group (n=52) for a period of 8 weeks. All patients received dietary and lifestyle advises before the start of trial. Anthropometric measurements, hepatic enzymes, and liver ultrasonography were assessed at baseline and after 8 weeks of follow-up. Results 87 subjects (n=44 and 43 in the curcumin and control group, respectively) completed the trial. Supplementation with curcumin was associated with a reduction in body mass index (–0.99±1.25 vs. – 0.15±1.31 in the curcumin and placebo groups, respectively; p=0.003) and waist circumference (–1.74±2.58 vs. –0.23±3.49 in the curcumin and placebo groups, respectively; p=0.024). Ultrasonographic findings were improved in 75.0% of subjects in the curcumin group, while the rate of improvement in the control group was 4.7% (p<0.001). Serum levels of aspartate aminotransferase and alanine aminotransferase were reduced by the end of trial in the curcumin group (p<0.001) but elevated in the control group (p<0.001). Curcumin was safe and well tolerated during the course of trial. Conclusion Short-term supplementation with curcumin improves liver fat and transaminase levels in patients with NAFLD.
UR - http://www.scopus.com/inward/record.url?scp=85011672061&partnerID=8YFLogxK
U2 - 10.1055/s-0043-100019
DO - 10.1055/s-0043-100019
M3 - Article
C2 - 28158893
AN - SCOPUS:85011672061
SN - 2194-9379
VL - 67
SP - 244
EP - 251
JO - Drug Research
JF - Drug Research
IS - 4
M1 - drugres2016-11-1304
ER -